Altrx" Altralinked" Polyethylene liners Description: An acetabular liner is one of the implant...
FDA Device Recall #Z-2220-2012 — Class II — July 24, 2012
Recall Summary
| Recall Number | Z-2220-2012 |
| Classification | Class II — Moderate risk |
| Date Initiated | July 24, 2012 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | DePuy Orthopaedics, Inc. |
| Location | Warsaw, IN |
| Product Type | Devices |
| Quantity | 20 liners |
Product Description
Altrx" Altralinked" Polyethylene liners Description: An acetabular liner is one of the implants used during total hip arthroplasty to replace the damaged hip joint to help increase patient mobility and to reduce pain. Packaging: Product is placed into a PETG tray, sealed with a Tyvek lid. This is placed into a second PETG tray and sealed with a Tyvek lid. This package is placed into a paperboard carton, labeled, and shrink-wrapped. Intended Use: An acetabular liner is used in combination with other implants for total hip arthroplasty is intended to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components.
Reason for Recall
In the recalled lot, the products were not machined according to the production router, a size 52 cup (122136052) was machined instead. This resulted in a size 52 liner being etched and labeled as a size 54 liner.
Distribution Pattern
Worldwide Distribution - USA including PA and the country of Canada
Lot / Code Information
Catalog number: 1221-36-054 and Lot Number: 231859
Other Recalls from DePuy Orthopaedics, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1456-2024 | Class II | ATTUNE AFFIXIUM Cementless Fixed Bearing Knee w... | Mar 12, 2024 |
| Z-1264-2023 | Class II | Attune Revision Limb Preservation System (LPS) ... | Feb 15, 2023 |
| Z-1267-2023 | Class II | Attune Posterior (PS) Fixed Bearing (FB) Tibial... | Feb 15, 2023 |
| Z-1263-2023 | Class II | Attune Revision Limb Preservation System (LPS) ... | Feb 15, 2023 |
| Z-1266-2023 | Class II | Attune Revision Limb Preservation System (LPS) ... | Feb 15, 2023 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.